VENMAX DRUGS AND PHARMACEUTICA
Healthcare › Pharmaceuticals & Biotechnology
₹15.65
at close · 21 Sept 2026
Latest filings
- NCLT orders shareholder meeting for Venmax Hatri Pharma merger · Strategic Transactions
- Venmax Drugs submits FY26 Annual Report; AGM on September 26, 2026 · Compliance
- Board approves 37th AGM notice, director changes and e-voting dates · Results
- Board meeting on Aug 31 to approve 37th AGM notice and annual report · Board & Shareholder Meetings
- Newspaper publication of quarter ended June 30 2026 results · Compliance
- Venmax Drugs: No deviation in preferential issue fund usage for Q1FY27 · Compliance
- Q1 FY27 Results: Revenue doubles YoY; 7.8L warrants forfeited · Results
- Q1 FY27 results: revenue up 105% YoY; board forfeits 7.8 lakh warrants · Results
- Board meeting on Aug 7 to approve Q1 results and forfeit warrants · Results
- 7,53,334 shares allotted on conversion of warrants · Fund Raising
- Warrant Conversion: 21.47 Lakh Equity Shares Allotted to 8 Non-Promoters · Fund Raising
- Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026. · Compliance
- Trading window closed pending June 2026 quarter results declaration · Compliance
- Statement of Deviation & variation for the Quarter and Year ended March 31, 2026. · Compliance
- Newspaper Advertisement of the Audited Financial results for the Quarter and Year ended March 31, 2026. · Compliance
- Audited Financial Results for the Quarter and Year ended March 31 , 2026 · Results
- Audited Financial Results for the Quarter and Year ended March 31, 2026 · Results
- Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 ,inter alia, to consider and approve Audited Standalone .... · Results
- <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> .... · Compliance
- Submission of Annual Secretarial Compliance Report for the year ended March 31, 2026. · Compliance
- Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. · Compliance
- Promoter confirms no encumbrance on shares for FY26 · Ownership Changes
- The Board has considered and approved the appointment of Mrs. Padmaja Kalyani Sadhanala as an Additional director, Non Executive and Non Independent Director and Mr. Revoor Ramachandra .... · Management Changes
- Approval of Modification of draft Scheme of Amalgamation submitted on November 12, 2025 between Hatri Pharma Private Limited (Transferor Company) and Venmax Drugs and Pharmaceuticals Limited .... · Strategic Transactions
- Intimation of Closure of Trading Window pursuant to declaration of Audited Financial Results for the Quarter and Year ended March 31, 2026. · Compliance
- Allotment of 28,00,000 Convertible warrants in to Equity shares on preferential basis and pursuant to Regulation 30 read with Schedule III of SEBI LODR Regulations, 2015 · Fund Raising
- Change in designation of Mr. Venkata Rao Sadhanala, whole Time director as Managing Director of the company for a period of 5 years w.e.f. March 11, 2026, subject to approval of shareholders. · Management Changes
- Newspaper Publication of unaudited financial results for the quarter and nine months ended December 31, 2025. · Compliance
- Statement of Deviation and Variation for the quarter ended December 31, 2025. · Compliance
- Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2025. · Results
- Outcome of the Board Meeting held on Saturday, February 7, 2026, i.e, today, to consider and approve the Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2025. · Results
- Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2026 ,inter alia, to consider and approve Unaudited .... · Results
- The Board of directors at its meeting held today i.e. January 21, 2026 has approved the conversion of 7,75,000 share warrants in to Equity. · Fund Raising
- Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended December 31, 2025. · Compliance
- Intimation of Closure of Trading Window for the Quarter ended December 31, 2025. · Compliance
- The board has considered and accepted the Resignation of Mrs . Dakshita Jain as Non Executive Independent Director of the company w.e.f. November 24, 2025. · Management Changes
- The Board has considered and accepted the resignation of Mrs. Dakshita Jain as Non Executive Independent Director of the Company w.e.f. November 24, 2025. · Management Changes
- Newspaper Publication of unaudited financials results for the Quarter and Half Year ended September 30, 2025. · Compliance
- Unaudited Financial Results For The Quarter and Half Year Ended September 30, 2025. · Results
- Outcome of the Board Meeting held on Wednesday, November 12, 2025, i.e, today, to consider and approve the un-audited financial results for the quarter and half year ended September 30, 2025. · Results
- Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 ,inter alia, to consider and approve Unaudited .... · Results
- Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2025. · Compliance
- Voting Results along with the Scrutinizers Report of the 36th AGM of the Company held on 27th September 2025 through VC/OAVM. · Board & Shareholder Meetings
- Summary of proceedings of the 36th Annual General Meeting of the Shareholders held at 10 AM through video conferencing mode. · Board & Shareholder Meetings
- Intimation of Closure of Trading Window for the Quarter and Half year ended September 30, 2025. · Compliance
- Revised outcome of Board Meeting held on 2nd September, 2025. · Board & Shareholder Meetings
- Submission of Annual Report for the Financial Year 2024-25 Pursuant to Regulation 34 and other relevant provisions of the SEBI (Listing Obligations & Disclosure Requirements), 2015. · Compliance
- Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. · Results
- Closure Trading Window for amalgamation of Venmax Drugs and Pharmaceuticals Limited with Hatri Pharma Private Limited. · Compliance
- Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/09/2025 ,inter alia, to consider and approve matters related .... · Strategic Transactions
Snapshot
What the business is, and whether it's a good one at a fair price.
A Pharmaceuticals & Biotechnology company listed on BSE, reporting revenue of ₹9 Cr over the trailing twelve months.
Market Cap
₹18 Cr
P / E (TTM)
38.2×
EV / EBITDA
54.8×
Div Yield
—
Growth
116.7%▲
Revenue 5y CAGR
PAT — · EBITDA —
Quality
-13.5%·
ROCE (5y median)
ROE -9.9% · margin 3.5%
Leverage
0.02·
Debt / Equity · low
Net debt ₹-1 Cr
Revenue FY21→FY26
47.8×▲
Margin +99.9 pts
₹0 Cr → ₹8 Cr
Cash conversion
-4.78×▼
Operating cash ÷ profit · 5 yrs
₹-11 Cr on ₹2 Cr
Moves on a normal day
2.98%·
Median daily move
Last 264 sessions · filing days run larger
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#107/170
P/B#33/164
ROCE#142/183
ROE#138/171
Debt / Equity#56/171
EBITDA margin#140/165
Revenue growth#9/161
Profit growth#22/158
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Revenue compounding 117% a year over 5 years
Debt at 0.02× equity
lower than 68% of its 171 Pharmaceuticals peers
Concerns
Erratic profits — up in only 2 of the last 5 years
Returns on capital -13.5% (5-year median)
#142 of 183 in Pharmaceuticals on the latest reported figures · down from 5.8% in FY21
Over 5 years it reported ₹2 Cr of profit and ₹-11 Cr of operating cash — -4.78×
Less than 60p of every ₹1 of profit arrived as cash
Charts
How has the market priced it — with filings on the timeline?
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from VENMAX DRUGS AND PHARMACEUTICA's filed financials and exchange disclosures
What does VENMAX DRUGS AND PHARMACEUTICA do?
VENMAX DRUGS AND PHARMACEUTICA is a Pharmaceuticals & Biotechnology company listed on BSE.
Is VENMAX DRUGS AND PHARMACEUTICA profitable?
Yes. Over the trailing twelve months VENMAX DRUGS AND PHARMACEUTICA reported a net profit of ₹0 Cr on revenue of ₹9 Cr.
Does VENMAX DRUGS AND PHARMACEUTICA pay a dividend?
Not in the latest reported year — VENMAX DRUGS AND PHARMACEUTICA's dividend payout for FY26 was nil.
Is VENMAX DRUGS AND PHARMACEUTICA debt-free?
Effectively yes. It holds ₹1 Cr more cash than debt. Debt stands at 0.02× equity.
Is VENMAX DRUGS AND PHARMACEUTICA expensive compared with its peers?
On trailing P/E, VENMAX DRUGS AND PHARMACEUTICA ranks 107 of 170 in Pharmaceuticals — cheaper than 37% of them, against an industry median of 29.6×. This is a position, not a valuation judgement.
How much does the VENMAX DRUGS AND PHARMACEUTICA share price move in a day?
On a typical session VENMAX DRUGS AND PHARMACEUTICA moves 2.98% — that is the median absolute close-to-close move across its last 264 trading days. Announcement days are routinely larger.
Where can I track VENMAX DRUGS AND PHARMACEUTICA's announcements?
Every NSE and BSE filing by VENMAX DRUGS AND PHARMACEUTICA appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.